Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20

Lantheus Holdings, Inc.

2025-Q1 EPS reported $1.02 revenue$372,764,000

Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.
PYLARIFY sales $257.7M (-0.5%); DEFINITY $79.2M (+3.5%).
FY2025 revenue guidance narrowed to $1.550B-$1.585B; adj EPS guidance lowered to $6.60-$6.70 from $7.00-$7.20.
Closed Evergreen Theragnostics; agreed to acquire Life Molecular Imaging (Q2); announced SPECT divestiture to SHINE (by year-end).
MK-6240 met endpoints in pivotal studies; NDA planned Q3 2025. PNT2002 will not proceed to NDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.